研究者業績

柳 茂

shigeru yanagi

基本情報

所属
学習院大学 理学部 生命科学科 教授
東京薬科大学 名誉教授
学位
博士(医学)(神戸大学)

研究者番号
60252003
J-GLOBAL ID
200901017245867806
researchmap会員ID
1000165476

外部リンク

元神戸大学教授の山村博平先生のご指導の下、チロシンキナーゼSykの研究に従事しました。その後、黒崎知博先生の下で、免疫系のシグナル伝達について解析を行いました。独立してより、神経発生、神経変性疾患、精神疾患の分子メカニズムと遺伝子治療について解析をしています。最近ではミトコンドリアユビキチンリガーゼMITOLの研究を精力的に行っています。


受賞

 1

論文

 100
  • Isshin Shiiba, Naoki Ito, Hijiri Oshio, Yuto Ishikawa, Takahiro Nagao, Hiroki Shimura, Kyu-Wan Oh, Eiki Takasaki, Fuya Yamaguchi, Ryoan Konagaya, Hisae Kadowaki, Hideki Nishitoh, Takehito Tanzawa, Shun Nagashima, Ayumu Sugiura, Yuuta Fujikawa, Keitaro Umezawa, Yasushi Tamura, Byung Il Lee, Yusuke Hirabayashi, Yasushi Okazaki, Tomohiro Sawa, Ryoko Inatome, Shigeru Yanagi
    Nature communications 16(1) 1508-1508 2025年2月10日  
    The proximal domains of mitochondria and the endoplasmic reticulum (ER) are linked by tethering factors on each membrane, allowing the efficient transport of substances, including lipids and calcium, between them. However, little is known about the regulation and function of mitochondria-ER contacts (MERCs) dynamics under mitochondrial damage. In this study, we apply NanoBiT technology to develop the MERBiT system, which enables the measurement of reversible MERCs formation in living cells. Analysis using this system suggests that induction of mitochondrial ROS increases MERCs formation via RMDN3 (also known as PTPIP51)-VAPB tethering driven by RMDN3 phosphorylation. Disruption of this tethering caused lipid radical accumulation in mitochondria, leading to cell death. The lipid radical transfer activity of the TPR domain in RMDN3, as revealed by an in vitro liposome assay, suggests that RMDN3 transfers lipid radicals from mitochondria to the ER. Our findings suggest a potential role for MERCs in cell survival strategy by facilitating the removal of mitochondrial lipid radicals under mitochondrial damage.
  • Motoi Tanabe, Yuga Saito, Ayaka Takasaki, Keita Nakano, Shunta Yamamoto, Chikako Suzuki, Nao Kawamura, Aki Hattori, Mami Oikawa, Shun Nagashima, Shigeru Yanagi, Tomoyuki Yamaguchi, Toshifumi Fukuda
    Cell reports 44(1) 115133-115133 2024年12月27日  
    During gestation, the choroid plexus (ChP) produces protein-rich cerebrospinal fluid and matures prior to brain development. It is assumed that ChP dysfunction has a profound effect on developmental neuropsychiatric disorders, such as autism spectrum disorder (ASD). However, the mechanisms linking immature ChP to the onset of ASD remain unclear. Here, we find that ChP-specific CAMDI-knockout mice develop an immature ChP alongside decreased multiciliogenesis and expression of differentiation marker genes following disruption of the cerebrospinal fluid barrier. These mice exhibit ASD-like behaviors, including anxiety and impaired socialization. Additionally, the administration of metformin, an FDA-approved drug, before the social critical period achieves ChP maturation and restores social behaviors. Furthermore, both the ASD model mice and organoids derived from patients with ASD developed an immature ChP. These results propose the involvement of an immature ChP in the pathogenesis of ASD and suggest the targeting of functional maturation of the ChP as a therapeutic strategy for ASD.
  • Hiroki Shimura, Sota Yamamoto, Isshin Shiiba, Mami Oikawa, Shohei Uchinomiya, Akio Ojida, Shigeru Yanagi, Hisae Kadowaki, Hideki Nishitoh, Toshifumi Fukuda, Shun Nagashima, Tomoyuki Yamaguchi
    Journal of biochemistry 2024年12月27日  
    Brown adipocytes are characterized by a high abundance of mitochondria, allowing them to consume fatty acids for heat production. Increasing the number of brown adipocytes is considered a promising strategy for combating obesity. However, the molecular mechanisms underlying their differentiation remain poorly understood. In this study, we demonstrate that etomoxir, an inhibitor of Carnitine Palmitoyltransferase 1 (CPT1), inhibits their differentiation through mechanisms independent of β-oxidation inhibition. In the presence of etomoxir during brown adipocyte differentiation, reduced expression of the thermogenic gene UCP1 and decreased lipid droplets formation were observed. Furthermore, a transient reduction in the expression of PPARγ2, a critical factor in adipocyte differentiation, was also observed in the presence of etomoxir. These findings suggest the presence of a regulatory mechanism that specifically enhances PPARγ2 expression during brown adipocyte differentiation, thereby modulating thermogenic gene expression.
  • Wenjuan Ma, Shah Adil Ishtiyaq Ahmad, Michihiro Hashimoto, Ahad Khalilnezhad, Miho Kataoka, Yuichiro Arima, Yosuke Tanaka, Shigeru Yanagi, Terumasa Umemoto, Toshio Suda
    The EMBO Journal 43(3) 339-361 2024年1月18日  
    Abstract Hematopoietic stem cell (HSC) divisional fate and function are determined by cellular metabolism, yet the contribution of specific cellular organelles and metabolic pathways to blood maintenance and stress-induced responses in the bone marrow remains poorly understood. The outer mitochondrial membrane-localized E3 ubiquitin ligase MITOL/MARCHF5 (encoded by the Mitol gene) is known to regulate mitochondrial and endoplasmic reticulum (ER) interaction and to promote cell survival. Here, we investigated the functional involvement of MITOL in HSC maintenance by generating MX1-cre inducible Mitol knockout mice. MITOL deletion in the bone marrow resulted in HSC exhaustion and impairment of bone marrow reconstitution capability in vivo. Interestingly, MITOL loss did not induce major mitochondrial dysfunction in hematopoietic stem and progenitor cells. In contrast, MITOL deletion induced prolonged ER stress in HSCs, which triggered cellular apoptosis regulated by IRE1α. In line, dampening of ER stress signaling by IRE1α inihibitor KIRA6 partially rescued apoptosis of long-term-reconstituting HSC. In summary, our observations indicate that MITOL is a principal regulator of hematopoietic homeostasis and protects blood stem cells from cell death through its function in ER stress signaling.
  • Shun Nagashima, Naoki Ito, Isshin Shiiba, Hiroki Shimura, Shigeru Yanagi
    The Journal of Biochemistry 173(1) 1-11 2022年11月8日  査読有り
    Abstract Mitochondria are involved in various cellular processes, such as energy production, inflammatory responses, and cell death. Mitochondrial dysfunction is associated with many age-related diseases, including neurological disorders and heart failure. Mitochondrial quality is strictly maintained by mitochondrial dynamics linked to an adequate supply of phospholipids and other substances from the endoplasmic reticulum (ER). The outer mitochondrial membrane-localized E3 ubiquitin ligase MITOL/MARCHF5 is responsible for mitochondrial quality control through the regulation of mitochondrial dynamics, formation of mitochondria-ER contacts, and mitophagy. MITOL deficiency has been shown to impair mitochondrial function, cause an excessive inflammatory response, and increase vulnerability to stress, resulting in the exacerbation of the disease. In this study, we overview the ubiquitin-mediated regulation of mitochondrial function by MITOL and the relationship between MITOL and diseases.
  • Takeshi Tokuyama, Hideki Uosaki, Ayumu Sugiura, Gen Nishitai, Keisuke Takeda, Shun Nagashima, Isshin Shiiba, Naoki Ito, Taku Amo, Satoshi Mohri, Akiyuki Nishimura, Motohiro Nishida, Ayumu Konno, Hirokazu Hirai, Satoshi Ishido, Takahiro Yoshizawa, Takayuki Shindo, Shingo Takada, Shintaro Kinugawa, Ryoko Inatome, Shigeru Yanagi
    iScience 25(7) 104582-104582 2022年7月15日  査読有り
    Abnormal mitochondrial fragmentation by dynamin-related protein1 (Drp1) is associated with the progression of aging-associated heart diseases, including heart failure and myocardial infarction (MI). Here, we report a protective role of outer mitochondrial membrane (OMM)-localized E3 ubiquitin ligase MITOL/MARCH5 against cardiac senescence and MI, partly through Drp1 clearance by OMM-associated degradation (OMMAD). Persistent Drp1 accumulation in cardiomyocyte-specific MITOL conditional-knockout mice induced mitochondrial fragmentation and dysfunction, including reduced ATP production and increased ROS generation, ultimately leading to myocardial senescence and chronic heart failure. Furthermore, ischemic stress-induced acute downregulation of MITOL, which permitted mitochondrial accumulation of Drp1, resulted in mitochondrial fragmentation. Adeno-associated virus-mediated delivery of the MITOL gene to cardiomyocytes ameliorated cardiac dysfunction induced by MI. Our findings suggest that OMMAD activation by MITOL can be a therapeutic target for aging-associated heart diseases, including heart failure and MI.
  • Takuma Suzuki, Hiroaki Uchida, Tomoko Shibata, Yasuhiko Sasaki, Hitomi Ikeda, Mika Hamada-Uematsu, Ryota Hamasaki, Kosaku Okuda, Shigeru Yanagi, Hideaki Tahara
    Molecular therapy oncolytics 22 265-276 2021年9月24日  査読有り
    Most oncolytic virotherapy has thus far employed viruses deficient in genes essential for replication in normal cells but not in cancer cells. Intra-tumoral injection of such viruses has resulted in clinically significant anti-tumor effects on the lesions in the vicinity of the injection sites but not on distant visceral metastases. To overcome this limitation, we have developed a receptor-retargeted oncolytic herpes simplex virus employing a single-chain antibody for targeting tumor-associated antigens (RR-oHSV) and its modified version with additional mutations conferring syncytium formation (RRsyn-oHSV). We previously showed that RRsyn-oHSV exhibits preserved antigen specificity and an ∼20-fold higher tumoricidal potency in vitro relative to RR-oHSV. Here, we investigated the in vivo anti-tumor effects of RRsyn-oHSV using human cancer xenografts in immunodeficient mice. With only a single intra-tumoral injection of RRsyn-oHSV at very low doses, all treated tumors regressed completely. Furthermore, intra-venous administration of RRsyn-oHSV resulted in robust anti-tumor effects even against large tumors. We found that these potent anti-tumor effects of RRsyn-oHSV may be associated with the formation of long-lasting tumor cell syncytia not containing non-cancerous cells that appear to trigger death of the syncytia. These results strongly suggest that cancer patients with distant metastases could be effectively treated with our RRsyn-oHSV.
  • Yasushige Aoyagi, Yoshihiro Hayashi, Yuka Harada, Kwangmin Choi, Natsumi Matsunuma, Daichi Sadato, Yuki Maemoto, Akihiro Ito, Shigeru Yanagi, Daniel T Starczynowski, Hironori Harada
    Cancer discovery 2021年8月30日  査読有り
    Ineffective hematopoiesis is a fundamental process leading to the pathogenesis of myelodysplastic syndromes (MDS). However, the pathobiological mediators of ineffective hematopoiesis in MDS remain unclear. Here, we demonstrated that overwhelming mitochondrial fragmentation in mutant hematopoietic stem cells and progenitors (HSC/Ps) triggers ineffective hematopoiesis in MDS. Mouse modeling of CBL exon-deletion with RUNX1 mutants, previously unreported co-mutations in MDS patients, recapitulated not only clinically relevant MDS phenotypes but also a distinct MDS-related gene signature. Mechanistically, dynamin-related protein 1 (DRP1)-dependent excessive mitochondrial fragmentation in HSC/Ps led to excessive ROS production, induced inflammatory signaling activation, and promoted subsequent dysplasia formation and impairment of granulopoiesis. Mitochondrial fragmentation was generally observed in patients with MDS. Pharmacological inhibition of DRP1 attenuated mitochondrial fragmentation and rescued ineffective hematopoiesis phenotypes in MDS mice. These findings provide mechanistic insights into ineffective hematopoiesis and indicate that dysregulated mitochondrial dynamics could be a therapeutic target for bone marrow failure in MDS.
  • Hiroki Kitakata, Jin Endo, Hirokazu Matsushima, Shoichi Yamamoto, Hidehiko Ikura, Akeo Hirai, Seien Koh, Genki Ichihara, Takahiro Hiraide, Hidenori Moriyama, Kohsuke Shirakawa, Shinichi Goto, Yoshinori Katsumata, Atsushi Anzai, Masaharu Kataoka, Takeshi Tokuyama, Satoshi Ishido, Shigeru Yanagi, Keiichi Fukuda, Motoaki Sano
    Journal of molecular and cellular cardiology 161 116-129 2021年8月11日  査読有り
    MITOL/MARCH5 is an E3 ubiquitin ligase that plays a crucial role in the control of mitochondrial quality and function. However, the significance of MITOL in cardiomyocytes under physiological and pathological conditions remains unclear. First, to determine the significance of MITOL in unstressed hearts, we assessed the cellular changes with the reduction of MITOL expression by siRNA in neonatal rat primary ventricular cardiomyocytes (NRVMs). MITOL knockdown in NRVMs induced cell death via ferroptosis, a newly defined non-apoptotic programmed cell death, even under no stress conditions. This phenomenon was observed only in NRVMs, not in other cell types. MITOL knockdown markedly reduced mitochondria-localized GPX4, a key enzyme associated with ferroptosis, promoting accumulation of lipid peroxides in mitochondria. In contrast, the activation of GPX4 in MITOL knockdown cells suppressed lipid peroxidation and cell death. MITOL knockdown reduced the glutathione/oxidized glutathione (GSH/GSSG) ratio that regulated GPX4 expression. Indeed, the administration of GSH or N-acetylcysteine improved the expression of GPX4 and viability in MITOL-knockdown NRVMs. MITOL-knockdown increased the expression of the glutathione-degrading enzyme, ChaC glutathione-specific γ-glutamylcyclotransferase 1 (Chac1). The knockdown of Chac1 restored the GSH/GSSG ratio, GPX4 expression, and viability in MITOL-knockdown NRVMs. Further, in cultured cardiomyocytes stressed with DOX, both MITOL and GPX4 were reduced, whereas forced-expression of MITOL suppressed DOX-induced ferroptosis by maintaining GPX4 content. Additionally, MITOL knockdown worsened vulnerability to DOX, which was almost completely rescued by treatment with ferrostatin-1, a ferroptosis inhibitor. In vivo, cardiac-specific depletion of MITOL did not produce obvious abnormality, but enhanced susceptibility to DOX toxicity. Finally, administration of ferrostatin-1 suppressed exacerbation of DOX-induced myocardial damage in MITOL-knockout hearts. The present study demonstrates that MITOL determines the cell fate of cardiomyocytes via the ferroptosis process and plays a key role in regulating vulnerability to DOX treatment. (288/300).
  • Shohei Okuda, Mariko Sato, Saho Kato, Shun Nagashima, Ryoko Inatome, Shigeru Yanagi, Toshifumi Fukuda
    The Journal of biological chemistry 297(2) 100986-100986 2021年7月20日  査読有り
    Radial migration during cortical development is required for formation of the six-layered structure of the mammalian cortex. Defective migration of neurons is linked to several developmental disorders such as autism and schizophrenia. A unique swollen structure called the dilation is formed in migrating neurons and is required for movement of the centrosome and nucleus. However, the detailed molecular mechanism by which this dilation forms is unclear. We report that CAMDI, a gene whose deletion is associated with psychiatric-behavior, is degraded by Cdc20-APC/C cell-cycle machinery after centrosome migration into the dilation in mouse brain development. We also show that CAMDI is restabilized in the dilation until the centrosome enters the dilation, at which point it is once again immediately destabilized. CAMDI degradation is carried out by binding to Cdc20-APC/C via the destruction box (D-box) degron of CAMDI. CAMDI D-box mutant overexpression inhibits dilation formation and neuronal cell migration via maintaining the stabilized state of CAMDI. These results indicate that CAMDI is a substrate of the Cdc20-APC/C system and that the oscillatory regulation of CAMDI protein correlates with dilation formation for proper cortical migration.
  • Ji Zhang, Yoshihiro Matsumura, Yuka Kano, Ayano Yoshida, Takeshi Kawamura, Hiroyuki Hirakawa, Takeshi Inagaki, Toshiya Tanaka, Hiroshi Kimura, Shigeru Yanagi, Kiyoko Fukami, Takefumi Doi, Timothy F Osborne, Tatsuhiko Kodama, Hiroyuki Aburatani, Juro Sakai
    Genes to cells : devoted to molecular & cellular mechanisms 26(7) 513-529 2021年7月  査読有り
    The lysine methyltransferase SETDB1, an enzyme responsible for methylation of histone H3 at lysine 9, plays a key role in H3K9 tri-methylation-dependent silencing of endogenous retroviruses and developmental genes. Recent studies have shown that ubiquitination of human SETDB1 complements its catalytic activity and the silencing of endogenous retroviruses in human embryonic stem cells. However, it is not known whether SETDB1 ubiquitination is essential for its other major role in epigenetic silencing of developmental gene programs. We previously showed that SETDB1 contributes to the formation of H3K4/H3K9me3 bivalent chromatin domains that keep adipogenic Cebpa and Pparg genes in a poised state for activation and restricts the differentiation potential of pre-adipocytes. Here, we show that ubiquitin-resistant K885A mutant of SETDB1 represses adipogenic genes and inhibits pre-adipocyte differentiation similar to wild-type SETDB1. We show this was due to a compensation mechanism for H3K9me3 chromatin modifications on the Cebpa locus by other H3K9 methyltransferases Suv39H1 and Suv39H2. In contrast, the K885A mutant did not repress other SETDB1 target genes such as Tril and Gas6 suggesting SETDB1 represses its target genes by two mechanisms; one that requires its ubiquitination and another that still requires SETDB1 but not its enzyme activity.
  • Naoki Ito, Takara Takahashi, Isshin Shiiba, Shun Nagashima, Ryoko Inatome, Shigeru Yanagi
    Journal of biochemistry 171(5) 529-541 2021年5月  査読有り
    The transfer of phospholipids from the endoplasmic reticulum to mitochondria via the mitochondria-endoplasmic reticulum (ER) contact site (MERCS) is essential for maintaining mitochondrial function and integrity. Here, we identified RMDN3/PTPIP51, possessing phosphatidic acid (PA)-transfer activity, as a neighboring protein of the mitochondrial E3 ubiquitin ligase MITOL/MARCH5 by proximity-dependent biotin labeling using APEX2. We found that MITOL interacts with and ubiquitinates RMDN3. Mutational analysis identified lysine residue 89 in RMDN3 as a site of ubiquitination by MITOL. Loss of MITOL or the substitution of lysine 89 to arginine in RMDN3 significantly reduced the PA-binding activity of RMDN3, suggesting that MITOL regulates the transport of PA to mitochondria by activating RMDN3. Our findings imply that ubiquitin signaling regulates phospholipid transport at the MERCS.
  • Mikihiro Mitsubori, Keisuke Takeda, Shun Nagashima, Satoshi Ishido, Masaaki Matsuoka, Ryoko Inatome, Shigeru Yanagi
    Biochemical and Biophysical Research Communications 549 67-74 2021年4月16日  査読有り
    Amyloid-β (Aβ) plaques are strongly associated with the development of Alzheimer's disease (AD). However, it remains unclear how morphological differences in Aβ plaques determine the pathogenesis of Aβ. Here, we categorized Aβ plaques into four types based on the macroscopic features of the dense core, and found that the Aβ-plaque subtype containing a larger dense core showed the strongest association with neuritic dystrophy. Astrocytes dominantly accumulated toward these expanded/dense-core-containing Aβ plaques. Previously, we indicated that deletion of the mitochondrial ubiquitin ligase MITOL/MARCH5 triggers mitochondrial impairments and exacerbates cognitive decline in a mouse model with AD-related Aβ pathology. In this study, MITOL deficiency accelerated the formation of expanded/dense-core-containing Aβ plaques, which showed reduced contacts with astrocytes, but not microglia. Our findings suggest that expanded/dense-core-containing Aβ-plaque formation enhanced by the alteration of mitochondrial function robustly contributes to the exacerbation of Aβ neuropathology, at least in part, through the reduced contacts between Aβ plaques and astrocytes.
  • Shun Nagashima, Naoki Ito, Reiki Kobayashi, Isshin Shiiba, Hiroki Shimura, Toshifumi Fukuda, Hideo Hagihara, Tsuyoshi Miyakawa, Ryoko Inatome, Shigeru Yanagi
    The Journal of Biological Chemistry 100620-100620 2021年3月31日  査読有り
    Mouse models of various neuropsychiatric disorders, such as schizophrenia, often display an immature dentate gyrus, characterized by increased numbers of immature neurons and neuronal progenitors and a dearth of mature neurons. We previously demonstrated that the CRMP5-associated GTPase (CRAG), a short splice variant of Centaurin-γ3/AGAP3, is highly expressed in the dentate gyrus. CRAG promotes cell survival and antioxidant defense by inducing the activation of serum response factors at promyelocytic leukemia protein bodies, which are nuclear stress-responsive domains, during neuronal development. However, the physiological role of CRAG in neuronal development remains unknown. Here, we analyzed the role of CRAG using dorsal forebrain-specific CRAG/Centaurin-γ3 knockout mice. The mice revealed maturational abnormality of the hippocampal granule cells, including increased doublecortin-positive immature neurons and decreased calbindin-positive mature neurons, a typical phenotype of immature dentate gyri. Furthermore, the mice displayed hyperactivity in the open-field test, a common measure of exploratory behavior, suggesting that these mice may serve as a novel model for neuropsychiatric disorder associated with hyperactivity. Thus, we conclude that CRAG is required for the maturation of neurons in the dentate gyrus, raising the possibility that its deficiency might promote the development of psychiatric disorders in humans.
  • Keisuke Takeda, Aoi Uda, Mikihiro Mitsubori, Shun Nagashima, Hiroko Iwasaki, Naoki Ito, Isshin Shiiba, Satoshi Ishido, Masaaki Matsuoka, Ryoko Inatome, Shigeru Yanagi
    Communications Biology 4(1) 192-192 2021年2月12日  査読有り
    Mitochondrial pathophysiology is implicated in the development of Alzheimer's disease (AD). An integrative database of gene dysregulation suggests that the mitochondrial ubiquitin ligase MITOL/MARCH5, a fine-tuner of mitochondrial dynamics and functions, is downregulated in patients with AD. Here, we report that the perturbation of mitochondrial dynamics by MITOL deletion triggers mitochondrial impairments and exacerbates cognitive decline in a mouse model with AD-related Aβ pathology. Notably, MITOL deletion in the brain enhanced the seeding effect of Aβ fibrils, but not the spontaneous formation of Aβ fibrils and plaques, leading to excessive secondary generation of toxic and dispersible Aβ oligomers. Consistent with this, MITOL-deficient mice with Aβ etiology exhibited worsening cognitive decline depending on Aβ oligomers rather than Aβ plaques themselves. Our findings suggest that alteration in mitochondrial morphology might be a key factor in AD due to directing the production of Aβ form, oligomers or plaques, responsible for disease development.
  • Isshin Shiiba, Keisuke Takeda, Shun Nagashima, Naoki Ito, Takeshi Tokuyama, Shun-Ichi Yamashita, Tomotake Kanki, Toru Komatsu, Yasuteru Urano, Yuuta Fujikawa, Ryoko Inatome, Shigeru Yanagi
    EMBO Reports 22(3) e49097 2021年2月10日  査読有り
    Parkin promotes cell survival by removing damaged mitochondria via mitophagy. However, although some studies have suggested that Parkin induces cell death, the regulatory mechanism underlying the dual role of Parkin remains unknown. Herein, we report that mitochondrial ubiquitin ligase (MITOL/MARCH5) regulates Parkin-mediated cell death through the FKBP38-dependent dynamic translocation from the mitochondria to the ER during mitophagy. Mechanistically, MITOL mediates ubiquitination of Parkin at lysine 220 residue, which promotes its proteasomal degradation, and thereby fine-tunes mitophagy by controlling the quantity of Parkin. Deletion of MITOL leads to accumulation of the phosphorylated active form of Parkin in the ER, resulting in FKBP38 degradation and enhanced cell death. Thus, we have shown that MITOL blocks Parkin-induced cell death, at least partially, by protecting FKBP38 from Parkin. Our findings unveil the regulation of the dual function of Parkin and provide a novel perspective on the pathogenesis of PD.
  • Isshin Shiiba, Keisuke Takeda, Shun Nagashima, Shigeru Yanagi
    International journal of molecular sciences 21(11) 2020年5月27日  査読有り
    The molecular pathology of diseases seen from the mitochondrial axis has become more complex with the progression of research. A variety of factors, including the failure of mitochondrial dynamics and quality control, have made it extremely difficult to narrow down drug discovery targets. We have identified MITOL (mitochondrial ubiquitin ligase: also known as MARCH5) localized on the mitochondrial outer membrane and previously reported that it is an important regulator of mitochondrial dynamics and mitochondrial quality control. In this review, we describe the pathological aspects of MITOL revealed through functional analysis and its potential as a drug discovery target.
  • Keigo Matsuno, Shun Nagashima, Isshin Shiiba, Keito Taniwaka, Keisuke Takeda, Takeshi Tokuyama, Naoki Ito, Nobuko Matsushita, Toshifumi Fukuda, Satoshi Ishido, Ryoko Inatome, Shigeru Yanagi
    Journal of biochemistry 168(3) 305-312 2020年4月17日  査読有り
    In mitochondrial disorders, short stature and growth failure are common symptoms, but their underlying mechanism remains unknown. In this study, we examined the cause of growth failure of mice induced by nestin promoter-driven knockout of the mitochondrial ubiquitin ligase MITOL (MARCH5), a key regulator of mitochondrial function. MITOL-knockout mice have congenital hypoplasia of the anterior pituitary caused by decreased expression of pituitary transcript factor 1 (Pit1). Consistently, both mRNA levels of growth hormone (GH) and prolactin levels were markedly decreased in the anterior pituitary of mutant mice. Growth failure of mutant mice was partly rescued by hypodermic injection of recombinant GH. To clarify whether this abnormality was induced by the primary effect of MITOL knockdown in the anterior pituitary or a secondary effect of other lesions, we performed lentiviral-mediated knockdown of MITOL on cultured rat pituitary GH3 cells, which secrete GH. GH production was severely compromised in MITOL-knockdown GH3 cells. In conclusion, MITOL plays a critical role in the development of the anterior pituitary; therefore, mice with MITOL dysfunction exhibited pituitary dwarfism caused by anterior pituitary hypoplasia. Our findings suggest that mitochondrial dysfunction is commonly involved in the unknown pathogenesis of pituitary dwarfism.
  • Takeshi Tokuyama, Asei Hirai, Isshin Shiiba, Naoki Ito, Keigo Matsuno, Keisuke Takeda, Kanata Saito, Koki Mii, Nobuko Matsushita, Toshifumi Fukuda, Ryoko Inatome, Shigeru Yanagi
    Biomolecules 10(3) 2020年3月13日  査読有り
    Mitochondria are highly dynamic organelles that constantly fuse, divide, and move, and their function is regulated and maintained by their morphologic changes. Mitochondrial disease (MD) comprises a group of disorders involving mitochondrial dysfunction. However, it is not clear whether changes in mitochondrial morphology are related to MD. In this study, we examined mitochondrial morphology in fibroblasts from patients with MD (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) and Leigh syndrome). We observed that MD fibroblasts exhibited significant mitochondrial fragmentation by upregulation of Drp1, which is responsible for mitochondrial fission. Interestingly, the inhibition of mitochondrial fragmentation by Drp1 knockdown enhanced cellular toxicity and led to cell death in MD fibroblasts. These results suggest that mitochondrial fission plays a critical role in the attenuation of mitochondrial damage in MD fibroblasts.
  • Shun Nagashima, Keisuke Takeda, Isshin Shiiba, Mizuho Higashi, Toshifumi Fukuda, Takeshi Tokuyama, Nobuko Matsushita, Seiichi Nagano, Toshiyuki Araki, Mari Kaneko, Go Shioi, Ryoko Inatome, Shigeru Yanagi
    Scientific reports 9(1) 20107-20107 2019年12月27日  査読有り
    CRMP-5-associated GTPase (CRAG), a short splicing variant of centaurin-γ3/AGAP3, is predominantly expressed in the developing brain. We previously demonstrated that CRAG, but not centaurin-γ3, translocates to the nucleus and activates the serum response factor (SRF)-c-Fos pathway in cultured neuronal cells. However, the physiological relevance of CRAG in vivo is unknown. Here, we found that CRAG/centaurin-γ3-knockout mice showed intensively suppressed kainic acid-induced c-fos expression in the hippocampus. Analyses of molecular mechanisms underlying CRAG-mediated SRF activation revealed that CRAG has an essential role in GTPase activity, interacts with ELK1 (a co-activator of SRF), and activates SRF in an ELK1-dependent manner. Furthermore, CRAG and ELK1 interact with promyelocytic leukaemia bodies through SUMO-interacting motifs, which is required for SRF activation. These results suggest that CRAG plays a critical role in ELK1-dependent SRF-c-fos activation at promyelocytic leukaemia bodies in the developing brain.
  • Mariko Kinoshita-Kawada, Hiroshi Hasegawa, Tsunaki Hongu, Shigeru Yanagi, Yasunori Kanaho, Ichiro Masai, Takayasu Mishima, Xiaoping Chen, Yoshio Tsuboi, Yi Rao, Junichi Yuasa-Kawada, Jane Y. Wu
    BIO-PROTOCOL 9(19) e3373 2019年9月  査読有り
  • Nagashima S, Takeda K, Ohno N, Ishido S, Aoki M, Saitoh Y, Takada T, Tokuyama T, Sugiura A, Fukuda T, Matsushita N, Inatome R, Yanagi S
    Life Science Alliance 2(4) 2019年8月  査読有り
  • Takeda K, Nagashima S, Shiiba I, Uda A, Tokuyama T, Ito N, Fukuda T, Matsushita N, Ishido S, Iwawaki T, Uehara T, Inatome R, Yanagi S
    The EMBO journal 38(15) 2019年6月  査読有り
  • Kinoshita-Kawada M, Hasegawa H, Hongu T, Yanagi S, Kanaho Y, Masai I, Mishima T, Chen X, Tsuboi Y, Rao Y, Yuasa-Kawada J, Wu JY
    Development 146(3) 2019年2月  査読有り
  • Keisuke Takeda, Shun Nagashima, Isshin Shiiba, Aoi Uda, Takeshi Tokuyama, Naoki Ito, Toshifumi Fukuda, Nobuko Matsushita, Satoshi Ishido, Takao Iwawaki, Takashi Uehara, Ryoko Inatome, Shigeru Yanagi
    EMBO Journal 2019年  
  • Takeda K, Yanagi S
    Molecular & cellular oncology 6(6) e1659078-e1659078 2019年  査読有り
  • Toshifumi Fukuda, Shun Nagashima, Ryoko Inatome, Shigeru Yanagi
    PloS one 14(11) e0224967 2019年  査読有り
    Little is known about the molecular mechanisms of cognitive deficits in psychiatric disorders. CAMDI is a psychiatric disorder-related factor, the deficiency of which in mice results in delayed neuronal migration and psychiatrically abnormal behaviors. Here, we found that CAMDI-deficient mice exhibited impaired recognition memory and spatial reference memory. Knockdown of CAMDI in hippocampal neurons increased the amount of internalized alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor (AMPAR) and attenuated the chemical long-term potentiation (LTP)-dependent cell surface expression of AMPAR. KIBRA was identified as a novel CAMDI-binding protein that retains AMPAR in the cytosol after internalization. KIBRA inhibited CAMDI-dependent Rab11 activation, thereby attenuating AMPAR cell surface expression. These results suggest that CAMDI regulates AMPAR cell surface expression during LTP. CAMDI dysfunction may partly explain the mechanism underlying cognitive deficits in psychiatric diseases.
  • Arasaki K, Nagashima H, Kurosawa Y, Kimura H, Nishida N, Dohmae N, Yamamoto A, Yanagi S, Wakana Y, Inoue H, Tagaya M
    EMBO reports 19(8) 2018年8月  査読有り
  • Maruyama T, Baba T, Maemoto Y, Hara-Miyauchi C, Hasegawa-Ogawa M, Okano HJ, Enda Y, Matsumoto K, Arimitsu N, Nakao K, Hamamoto H, Sekimizu K, Ohto-Nakanishi T, Nakanishi H, Tokuyama T, Yanagi S, Tagaya M, Tani K
    Cell death & disease 9(8) 797-797 2018年7月  査読有り
  • T. Tohgasaki, N. Ozawa, T. Yoshino, S. Ishiwatari, S. Matsukuma, S. Yanagi, H. Fukuda
    International Journal of Cosmetic Science 40(2) 178-186 2018年4月1日  査読有り
  • Toshifumi Fukuda, Shigeru Yanagi
    CELLULAR AND MOLECULAR LIFE SCIENCES 74(19) 3533-3552 2017年10月  査読有り
  • Toshifumi Fukuda, Shun Nagashima, Takaya Abe, Hiroshi Kiyonari, Ryoko Inatome, Shigeru Yanagi
    EMBO REPORTS 17(12) 1785-1798 2016年12月  査読有り
  • Wataru Mizushima, Hidehisa Takahashi, Masashi Watanabe, Shintaro Kinugawa, Shouji Matsushima, Shingo Takada, Takashi Yokota, Takaaki Furihata, Junichi Matsumoto, Masaya Tsuda, Ikuru Chiba, Shun Nagashima, Shigeru Yanagi, Masaki Matsumoto, Keiichi I. Nakayama, Hiroyuki Tsutsui, Shigetsugu Hatakeyama
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY 100 43-53 2016年11月  査読有り
  • Nobuko Matsushita, Midori Suzuki, Emi Ikebe, Shun Nagashima, Ryoko Inatome, Kenichi Asano, Masato Tanaka, Masayuki Matsushita, Eisaku Kondo, Hidekatsu Iha, Shigeru Yanagi
    SCIENTIFIC REPORTS 6 31266 2016年8月  査読有り
  • Yoshio Hoshiba, Tomohisa Toda, Haruka Ebisu, Mayu Wakimoto, Shigeru Yanagi, Hiroshi Kawasaki
    JOURNAL OF NEUROSCIENCE 36(21) 5775-5784 2016年5月  査読有り
  • Mizuho Homma, Shun Nagashima, Toshifumi Fukuda, Shigeru Yanagi, Hiroyoshi Miyakawa, Emiko Suzuki, Takako Morimoto
    EUROPEAN JOURNAL OF NEUROSCIENCE 40(8) 3158-3170 2014年10月  査読有り
  • H. Saida, Y. Matsuzaki, K. Takayama, A. Iizuka, A. Konno, S. Yanagi, H. Hirai
    GENE THERAPY 21(9) 820-827 2014年9月  査読有り
  • Shun Nagashima, Takeshi Tokuyama, Ryo Yonashiro, Ryoko Inatome, Shigeru Yanagi
    JOURNAL OF BIOCHEMISTRY 155(5) 273-279 2014年5月  査読有り
  • Ayumu Konno, Anton N. Shuvaev, Noriko Miyake, Koichi Miyake, Akira Iizuka, Serina Matsuura, Fathul Huda, Kazuhiro Nakamura, Shigeru Yanagi, Takashi Shimada, Hirokazu Hirai
    CEREBELLUM 13(1) 29-41 2014年2月  査読有り
  • Ayumu Sugiura, Shun Nagashima, Takeshi Tokuyama, Taku Amo, Yohei Matsuki, Satoshi Ishido, Yoshihisa Kudo, Heidi M. McBride, Toshifumi Fukuda, Nobuko Matsushita, Ryoko Inatome, Shigeru Yanagi
    MOLECULAR CELL 51(1) 20-34 2013年7月  査読有り
  • Nishiyama T, Hasegawa E, Yanagi S, Kudo Y, Hamada R, Matsumura N, Tomino M, Muromachi Y, Hatakeyama K, Uchino H
    Acta neurochirurgica. Supplement 118 65-70 2013年  査読有り
  • Ryo Yonashiro, Yuya Kimijima, Takuya Shimura, Kohei Kawaguchi, Toshifumi Fukuda, Ryoko Inatome, Shigeru Yanagi
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 109(7) 2382-2387 2012年2月  査読有り
  • Shun Nagashima, Toshifumi Fukuda, Yuka Kubota, Ayumu Sugiura, Mitsuyoshi Nakao, Ryoko Inatome, Shigeru Yanagi
    JOURNAL OF BIOLOGICAL CHEMISTRY 286(39) 33879-33889 2011年9月  査読有り
  • Matsushita N, Endo Y, Sato K, Kurumizaka H, Yamashita T, Takata M, Yanagi S
    PloS one 6(8) e23324 2011年8月  査読有り
  • Zen Kouchi, Takahiro Igarashi, Nami Shibayama, Shunichi Inanobe, Kazuyuki Sakurai, Hideki Yamaguchi, Toshifumi Fukuda, Shigeru Yanagi, Yoshikazu Nakamura, Kiyoko Fukami
    JOURNAL OF BIOLOGICAL CHEMISTRY 286(10) 8459-8471 2011年3月  査読有り
  • Nobuko Matsushita, Ryo Yonashiro, Yoshinobu Ogata, Ayumu Sugiura, Shun Nagashima, Toshifumi Fukuda, Ryoko Inatome, Shigeru Yanagi
    GENES TO CELLS 16(2) 190-202 2011年2月  査読有り
  • Ayumu Sugiura, Ryo Yonashiro, Toshifumi Fukuda, Nobuko Matsushita, Shun Nagashima, Ryoko Inatome, Shigeru Yanagi
    MITOCHONDRION 11(1) 139-146 2011年1月  査読有り
  • Toshifumi Fukuda, Satoko Sugita, Ryoko Inatome, Shigeru Yanagi
    JOURNAL OF BIOLOGICAL CHEMISTRY 285(52) 40554-40561 2010年12月  査読有り
  • Shinji Takeuchi, Akiko Takahashi, Noriko Motoi, Shin Yoshimoto, Tomoko Tajima, Kimi Yamakoshi, Atsushi Hirao, Shigeru Yanagi, Kiyoko Fukami, Yuichi Ishikawa, Saburo Sone, Eiji Hara, Naoko Ohtani
    CANCER RESEARCH 70(22) 9381-9390 2010年11月  査読有り
  • Roland Mansson, Saori Morota, Magnus J. Hansson, Ichiro Sonoda, Yoshihiro Yasuda, Motohide Shimazu, Ayumu Sugiura, Shigeru Yanagi, Hitoshi Miura, Hiroyuki Uchino, Eskil Elmer
    HEPATOLOGY 51(1) 347-348 2010年1月  査読有り

MISC

 31

書籍等出版物

 5